Stem cell research

Technological progress opens up new fields of research in biology and medicine, as well as new approaches to therapy. As our understanding and our possibilities of intervening in complex biological processes grow, it is paramount to conduct research responsibly.

This applies in particular to research with human embryonic stem cells. A stem cell is a cell that has the ability to reproduce itself indefinitely and to give rise to the many specialized cells that make up the tissues and organs of the human body. Stem cells exist in several tissues of adults as well as in the fetus and embryo.

Our understanding of these cells is at an early stage; yet, they hold immense potential for combating diseases such as Parkinson's, Alzheimer's and diabetes.

The use of stem cell research remains controversial to many and is the subject of an ongoing international debate. For this reason, the ethical framework for research involving human stem cells must be clearly defined.

 

Ethics Committee

Novartis established in 2002 an Ethics Committee comprised of external, independent specialists to oversee the company's research efforts in the field of stem cell research and advise our Executive Committee on all bioethical issues of relevance for the company. This interdisciplinary body consists of seven members from diverse disciplines:

• human genetics
• cell biology
• patent legislation
• EU legislation
• philosophy/theology
• ethics

The role of the Committee is to carefully assess preclinical research projects involving human embryos and human embryonic stem cells in order to ensure compliance with the company's internal ethical guidelines.

Novartis acknowledges that human embryonic stem cell research is an evolving field and one characterized by ethical complexities. The role of our Ethics Committee is to help us establish criteria and procedures which strike the right balance between freedom of research and the legitimate demands of society.